CN101282745B - 用cd37-特异性和cd20-特异性结合分子减少b-细胞 - Google Patents
用cd37-特异性和cd20-特异性结合分子减少b-细胞 Download PDFInfo
- Publication number
- CN101282745B CN101282745B CN200680027227.9A CN200680027227A CN101282745B CN 101282745 B CN101282745 B CN 101282745B CN 200680027227 A CN200680027227 A CN 200680027227A CN 101282745 B CN101282745 B CN 101282745B
- Authority
- CN
- China
- Prior art keywords
- cell
- tru
- purposes
- binding molecules
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Abstract
Description
Bjab | 膜联蛋白V阳性 | |
无SMIP | 17.5 | |
CD20SMIP | 27 | |
CD37SMIP | 30.6 | |
CD19SMIP | 29.1 | |
CD20+CD37SMIP | 41 | |
CD20+CD19SMIP | 37.1 | |
CD37+CD19SMIP | 35.3 | |
+GAM | ||
Ramos | 膜联蛋白V阳性 | 膜联蛋白V阳性 |
仅细胞 | 3 | 3.3 |
CD20MAb | 1.4 | 3.1 |
CD37 Mab | 18.3 | 8.7 |
CD19 MAb | 3.7 | 3.1 |
CD40 MAb | 3.9 | 8.3 |
CD20+CD37 | 32.3 | 35.7 |
CD20+CD19 | 5 | 10.5 |
CD20+CD40 | 5.7 | 19.4 |
CD19+CD37 | 26.9 | 50 |
CD19+CD40 | 8.2 | 18.4 |
第90天无肿瘤小鼠百分比 | 存活时间中值(天) | |
TRU-016+利妥希玛(200μg) | 42 | 31 |
TRU-016+利妥希玛(100μg) | 25 | 24 |
TRU-016(200μg) | 20 | 16 |
利妥希玛(200μg) | 20 | 17 |
HuIgG | 0 | 10 |
第90天无肿瘤小鼠百分比 | 存活时间中值(天) | |
TRU-016(100μg) | 25 | 24 |
利妥希玛(100μg) | 0 | 17 |
HuIgG | 0 | 15 |
构建体No. | 描述 | 接头 | 铰链 | DNA SEQID NO: | AA SEQ IDNO: |
019001 | Vk3:VH5-51 | 15aagly4ser | SSC-P | 5 | 6 |
019002 | Vk3:VH5-51接头(TG-SS) | 15aagly4ser | SSC-P | 7 | 8 |
019003 | Vk3:VH5-51VH V11S | 15aagly4ser | SSC-P | 9 | 10 |
019004 | Vk3:VH5-51VK3,cdr1(E→Q) | 15aagly4ser | SSC-P | 11 | 12 |
019005 | Vk3:VH5-51VK3,cdr1(N→S) | 15aagly4ser | SSC-P | 13 | 14 |
019006 | Vk3:VH5-51VK3,cdr1(T→A) | 15aagly4ser | SSC-P | 15 | 16 |
019010 | mVk:VH5-5a | 15aagly4ser | SSC-P | 17 | 18 |
019011 | Vk3:mVH(接头G-S突变) | 15aagly4ser | SSC-P | 19 | 20 |
019017 | Vk3:VH5 VH3FW1 | 15aagly4ser | SSC-P | 21 | 22 |
019018 | mVH:Vk3 | 15aagly4ser | SSC-P | 23 | 24 |
019019 | Vk3:mVH(含2H7前导序列的019011) | 15aagly4ser | SSC-P | 25 | 26 |
019021 | mVH:Vk3 | 15aagly4ser | SSC-P | 27 | 28 |
019023 | Vk3:mVH(固定的019011GS4突变) | 15aagly4ser | SSC-P | 29 | 30 |
019024 | Vk3:mVH(固定的019011GS4突变) | 15aagly4ser | SSC-P | 31 | 32 |
019025 | Vk3:VH5 VH3FW1 | 15aagly4ser | SSC-P | 33 | 34 |
019026 | Vk3:VH5 VH3FW1 | 15aagly4ser | SSC-P | 35 | 36 |
019032 | Vk3:VH5 VH3-13 FW1 | 15aagly4ser | SSC-P | 37 | 38 |
019033 | Vk3:VH5 VH3-13FW1 | 15aagly4ser | SSC-P | 39 | 40 |
019034 | Vk3:VH5 VH3-13L11S FW1 | 15aagly4ser | SSC-P | 41 | 42 |
019035 | Vk3:VH5 VH3-13L11S FW1 | 15aagly4ser | SSC-P | 43 | 44 |
019037 | Vk3(CDR-L1改变):VH5 | 15aagly4ser | SSC-P | 45 | 46 |
019041 | 019006-CDR-H3JH4 | 15aagly4ser | SSC-P | 47 | 48 |
019043 | 019006-CDR-H3JH6 | 15aagly4ser | SSC-P | 49 | 50 |
019044 | 019006-CDR-H3JH5a | 15aagly4ser | SSC-P | 51 | 52 |
019045 | 019006-CDR-H3JH5b | 15aagly4ser | SSC-P | 53 | 54 |
019046 | 019006-CDR-H3JH1 | 15aagly4ser | SSC-P | 55 | 56 |
019047 | 019006-CDR-H3JH3a | 15aagly4ser | SSC-P | 57 | 58 |
019048 | 019006-CDR-H3JH3b | 15aagly4ser | SSC-P | 59 | 60 |
019049 | 019006-CDR-H3JH2 | 15aagly4ser | SSC-P | 79 | 80 |
019050 | 019006-CDR-H2改变 | 15aagly4ser | SSC-P | 81 | 82 |
019051 | 019044 | 20aa | CPPCP | 83 | 84 |
gly4ser | |||||
019008 | 85 | 86 | |||
019009 | 87 | 88 |
铰链描述 | DNA或氨基酸序列 | SEQ IDNO: |
ccc(p)-hIgG1(DNA) | gagcccaaatcttgtgacaaaactcacacatgtccaccgtgccca | 89 |
ccc(p)-hIgG1(AA | EPKSCDKTHTCPPCP | 90 |
scc(p)-hIgG1(DNA) | gagcccaaatcttctgacaaaactcacacatgtccaccgtgccca | 91 |
scc(p)-hIgG1(AA) | EPKSSDKTHTCPPCP | 92 |
scc(s)-hIgG1(DNA) | gagcccaaatcttctgacaaaactcacacatgtccaccgtgctca | 93 |
scc(s)- | EPKSSDKTHTCPPCS | 94 |
hIgG1(AA) | ||
scs(s)-hIgG1(DNA) | gagcccaaatcttgtgacaaaactcacacatgtccaccgagctca | 95 |
scs(s)-hIgG1(AA) | EPKSSDKTHTCPPSS | 96 |
sss(p)-hIgG1(DNA) | gagcccaaatcttctgacaaaactcacacatctccaccgagccca | 97 |
sss(p)-hIgG1(AA) | EPKSSDKTHTSPPSP | 98 |
sss(s)-hIgG1(DNA) | gagcccaaatcttctgacaaaactcacacatctccaccgagctca | 99 |
sss(s)-hIgG1(AA) | EPKSSDKTHTSPPSS | 100 |
csc(p)-hIgG1(DNA) | gagcccaaatcttgtgacaaaactcacacatctccaccgtgccca | 101 |
csc(p)-hIgG1(AA) | EPKSCDKTHTSPPCP | 102 |
csc(s)-hIgG1(DNA) | gagcccaaatcttgtgacaaaactcacacatctccaccgtgctca | 103 |
csc(s)-hIgG1(AA) | EPKSCDKTHTSPPCS | 104 |
ssc(p)-hIgG1(DNA) | gagcccaaatcttctgacaaaactcacacatctccaccgtgccca | 105 |
ssc(p)-hIgG1(AA) | EPKSSDKTHTSPPCP | 106 |
scs(s)-hIgG1(DNA) | gagcccaaatcttctgacaaaactcacacatctccaccgtgctca | 107 |
scs(s)-hIgG1(AA) | EPKSSDKTHTSPPCS | 108 |
css(p)-hIgG1(DNA) | gagcccaaatcttgtgacaaaactcacacatctccaccgagccca | 109 |
css(p)-hIgG1(AA) | EPKSCDKTHTSPPSP | 110 |
css(s)-hIgG1(DNA) | gagcccaaatcttgtgacaaaactcacacatctccaccgagctca | 111 |
css(s)-hIgG1(AA) | EPKSCDKTHTSPPSS | 112 |
scs(s)-hIgG1 | gagcccaaatcttgtgacaaaactcacacatgtccaccgagctca | 113 |
(DNA) | ||
scs(s)-hIgG1(AA) | EPKSSDKTHTCPPSS | 114 |
hIgA1 | VPSTPPTPSPSTPPTPSPS | 115 |
hIgA2 | VPPPPP | 116 |
hIgG3(DNA) | gagctcaaaactcctctcggggatacgacccatacgtgtccccgctgtcctgaaccgaagtcctgcgatacgcctccgccatgtccacggtgcccagagcccaaatcatgcgatacgcccccaccgtgtccccgctgtcctgaaccaaagtcatgcgataccccaccaccatgtccaagatgccca | 117 |
hIgG3(AA) | ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCP EPKSCDTPPPCPRCP | 118 |
IgG315hscc(DNA) | gagcccaaatcttctgacacacctcccccatgcccacggtgcccc | 119 |
IgG315hscc(AA) | EPKSSDTPPPCPRCP | 120 |
IgG315hcss(DNA) | gagcccaaatcttgtgacacacctcccccatccccacggtcccca | 121 |
IgG315hcss(AA) | EPKSCDTPPPSPRSP | 122 |
IgG315hsss(DNA) | gagcccaaatcttctgacacacctcccccatccccacggtcccca | 123 |
IgG315hsss(AA) | EPKSSDTPPPSPRSP | 124 |
IgG3hl5csc(DNA) | gagcccaaatcttgtgacacacctcccccatccccacggtgccca | 125 |
IgG3hl5csc(AA) | EPKSCDTPPPSPRCP | 126 |
hlgD | ESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTP | 127 |
V-区 | 用于抗-CD37人源化的人VH构架区 | SEQ IDNO: |
FR1 | ||
VH1 | QVQLVQSGAEVKKPGASVKVSCKASGYTFT | 140 |
VH1 | QVQLVQSGAEVKKPGSSVKVSCKASGGTFS | 141 |
VH1 | QVQLVQSGAEVKKPGSSVKVSCKASGGTFS | 142 |
VH1 | EVQLVQSGAEVKKPGA1VKISCKVSGYTFT | 143 |
VH5 | EVQLVQSGAEVKKPGESLKISCKGSGYSFT | 144 |
VH5 | EVQLVQSGAEVKKPGESLRISCKGSGYSFT | 145 |
VH7 | QVQLVQSGSELKKPGASVKVSCKASGYTFT | 146 |
FR2 | ||
VH1 | WVRQAPGQGLEWMG | 147 |
VH1 | WVRQAPGQGLEWMG | 148 |
VH1 | WVRQAPGQGLEWMG | 149 |
VH1 | WVQQAPGKGLEWMG | 150 |
VH5 | WVRQMPGKGLEWMG | 151 |
VH5 | WVRQMPGKGLEWMG | 152 |
VH7 | WVRQAPGQGLEWMG | 153 |
FR3 | ||
VH1 | RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR | 154 |
VH1 | RVTITADESTSTAYMELSSLRSEDTAVYYCAR | 155 |
VH1 | RVTITADKSTSTAYMELSSLRSEDTAVYYCAR | 156 |
VH1 | RVTITADTSTDTAYMELSSLRSEDTAVYYCAT | 157 |
VH5 | QVTISADKSISTAYLQWSSLKASDTAMYYCAR | 158 |
VH5 | HVTISADKSISTAYLQWSSLKASDTAMYYCAR | 159 |
VH7 | RFVFSLDTSVSTAYLQISSLKAEDTAVYYCAR | 160 |
FR4 | ||
WGQGTLVTVSS | 161 | |
WGRGTLVTVSS | 162 | |
WGQGTMVTVSS | 163 | |
WGQGTMVTVSS | 164 | |
WGQGTLVTVSS | 165 | |
WGQGTLVTVSS | 166 | |
WGQGTLVTVSS | 167 | |
WGQGTTVTVSS | 168 | |
WGKGTTVTVSS | 169 | |
用于抗-CD37人源化的人VK构架区 | ||
FR1 | ||
VK3 | EIVMTQSPATLSVSPGERATLSC | 170 |
VK3 | EIVLTQSPATLSLSPGERATLSC | 171 |
VK1 | DIQMTQSPSSLSASVGDRVTITC | 172 |
VK1 | DIQMTQSPSSLSASVGDRVTITC | 173 |
VK1 | DIQMTQSPSSLSASVGDRVTITC | 174 |
VK1 | NIQMTQSPSAMSASVGDRVTITC | 175 |
VK1 | DIQMTQSPSSLSASVGDRVTITC | 176 |
VK1 | AIQLTQSPSSLSASVGDRVTITC | 177 |
VK1 | DIQLTQSPSFLSASVGDRVTITC | 178 |
VK1 | AIRMTQSPFSLSASVGDRVTITC | 179 |
VK1 | AIQMTQSPSSLSASVGDRVTITC | 180 |
VK1 | DIQMTQSPSTLSASVGDRVTITC | 181 |
FR2 | ||
VK3 | WYQQKPGQAPRLLIY | 182 |
VK3 | WYQQKPGQAPRLLIY | 183 |
VK1 | WYQQKPGKAPKLLIY | 184 |
VK1 | WYQQKPGKVPKLLIY | 185 |
VK1 | WYQQKPGKAPKRLIY | 186 |
VK1 | WFQQKPGKVPKHLIY | 187 |
VK1 | WFQQKPGKAPKSLIY | 188 |
VK1 | WYQQKPGKAPKLLIY | 189 |
VK1 | WYQQKPGKAPKLLIY | 190 |
VK1 | WYQQKPAKAPKLFIY | 191 |
VK1 | WYQQKPGKAPKLLIY | 192 |
VK1 | WYQQKPGKAPKLLIY | 193 |
FR3 | ||
VK3 | GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC | 194 |
VK3 | GIPARFSGSGSGTDFTLTISSLEPEDFAVYYC | 195 |
VK1 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | 196 |
VK1 | GVPSRFSGSGSGTDFTKTISSLQPEDVATYYC | 197 |
VK1 | GVPSRFSGSGSGTEFTLTISSLQPEDFATYYC | 198 |
VK1 | GVPSRFSGSGSGTEFTKTISSLQPEDFATYYC | 199 |
VK1 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | 200 |
VK1 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | 201 |
VK1 | GVPSRFSGSGSGTEFTLTISSLQPEDFATYYC | 202 |
VK1 | GVPSRFSGSGSGTDYTLTISSLQPEDFATYYC | 203 |
VK1 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | 204 |
VK1 | GVPSRFSGSGSGTEFTLTISSLQPDDFATYYC | 205 |
FR4 | ||
FGQGTKVEIK | 206 | |
FGQGTKLEIK | 207 | |
FGPGTKVDIK | 208 | |
FGGGTKVEIK | 209 | |
FGQGTRLEIK | 210 |
构建体# | SEQ IDNO: | DNA或氨基酸序列 |
019049 | 79 | aagcttgccgccatggaagccccagcgcagcttctcttcctcctgctactctggctcccagataccaccggagaaattgtgttgacacagtctccagccaccctgtctttgtctccaggcgaaagagccaccctctcctgccgagcaagtgaaaatgtttacagctacttagcctggtaccaacagaaacctggccaggctcctaggctcctcatctattttgcaaaaaccttagcagaaggaattccagccaggttcagtggcagtggatccgggacagacttcactctcaccatcagcagcctagagcctgaagattttgcagtttattactgtcaacatcattccgataatccgtggacattcggccaagggaccaaggtggaaatcaaaggtggcggtggctcgggcggtggtggatctggaggaggtgggaccggtgaggtgcagctggtgcagtctggagcagaggtgaaaaagcccggagagtctctgaagatttcctgtaagggatccggttactcattcactggctacaatatgaactgggtgcgccagatgcccgggaaaggcctcgagtggatgggcaatattgatccttattatggtggtactacctacaaccggaagttcaagggccaggtcactatctccgccgacaagtccatcagcaccgcctacctgcaatggagcagcctgaaggcctcggacaccgccatgtattactgtgcacgctcagtcggccctttcgacctctggggcagaggcaccctggtcactgtctcctctgatcaggagcccaaatcttctgacaaaactcacacatctccaccgtgcccagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga |
019049 | 80 | MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIKGGGGSGGGGSGGGGTGEVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDLWGRGTLVTVSSDQEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
019050 | 81 | aagcttgccgccatggaagccccagctcagcttctcttcctcctgctactctggctcccagataccaccggagaaatttgttgacacagtctccagccaccctgtctttgtctccaggcgaaagagccaccctctcctgccgagcaagtgaaaatgtttacagctacttagcctggtaccaacagaaacctggccaggctcctaggctcctcatctattttgcaaaaaccttagcagaaggaattccagccaggttcagtggcagtggatccgggacagacttcactctcaccatcagcagcctagagcctgaagattttgcagtttattactgtcaacatcattccgataatccgtggacattcggccaagggaccaaggtggaaatcaaaggtggcggtggctcgggcggtggtggatctggaggaggtggggctagcgaggtgcagctggtgcagtctggagcagaggtgaaaaagcccggagagtctctgaagatttcctgtaagggatccggttactcattcactagctacaatatgaactgggtgcgccagatgcccgggaaaggcctggagtggatgggcaatattgatccttattatggtggtactaactacgcccagaagttccagggccaggtcactatctccgccgacaagtccatcagcaccgcctacctgcaatggagcagcctgaaggcctcggacaccgccatgtattactgtgcacgctcagtcggccctatggactactggggccgcggcaccctggtcactgtctcctctgatcaggagcccaaatcttctgacaaaactcacacatctccaccgtgcccagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatga |
019050 | 82 | MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIKGGGGSGGGGSGGGGASEVQLVQSGAEVKKPGESLKISCKGSGYSFTSYNMNWVRQMPGKGLEWMGNIDPYYGGTNYAQKFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPMDYWGRGTLVTVSSDQEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
019051 | 83 | aagcttgccgccatggaagccccagcgcagcttctcttcctcctgctactctggctcccagataccaccggagaaatgtgttgacacagtctccagccaccctgtctttgtctccaggcgaaagagccaccctctcctgccgagcaagtgagaatgtttacagctacttagcctggtaccaacagaaacctggccaggctcctaggctcctcatctattttgcaaaaaccttagcagaagggattccagccagattcagtggcagtggttccgggacagacttcactctcaccatcagcagcctagagcctgaagattttgcagtttattactgtcaacatcattccgataatccgtggacattcggccaagggaccaaggtggaaatcaaaggtggcggtggctcgggcggtggtggatctggaggaggtgggagcggaggaggagctagcgaggtgcagctggtgcagtctggagcagaggtgaaaaagcccggagagtctctgaagatttcctgtaagggatccggttactcattcactggctacaatatgaactgggtgcgccagatgcccgggaaaggcctcgaatggatgggcaatattgatccttattatggtggtactacctacaaccggaagttcaagggccaggtcactatctccgccgacaagtccatcagcaccgcctacctgcaaggagcagcctgaaggcctcggacaccgccatgtattactgtgcacgctcagtcggccctttcgactcctggggccagggcaccctggtcactgtctcgagttgtccaccgtgcccagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtg gtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgactctaga |
019051 | 84 | MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIKGGGGSGGGGSGGGGSGGGASEVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSSCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
019008 | 85 | aagcttgccgccatggaagccccagctcagcttctcttcctcctgctactctggctcccagataccaccggagaaattgtgttgacacagtctccagccaccctgtctttgtctccaggcgaaagagccaccctctcctgccgaacaagtgaaaatgtttacagctacttagcctggtaccaacagaaacctggccaggctcctaggctcctcatctattttgcaaaaaccttagcagaaggaattccagccaggttcagtggcagtggatccgggacagacttcactctcaccatcagcagcctagagcctgaagattttgcagtttattactgtcaacatcattccgataatccgtggacattcggccaagggaccaaggtggaaatcaaaggtggcggtggctcgggcggtggtggatctggaggaggtgggaccggtgaggtgcagctggtgcagtctggagcagaggtgaaaaagcccggagagtctctgaagatttcctgtaagggatccggttactcattcactggctacaatatgaactgggtgcgccagatgcccgggaaaggcctggagtggatgggcaatattgatccttattatggtggtacta cctacaaccggaagttcaagggccaggtcactatctccgccgacaagtccatcagcaccgcctacctgcaatggagcagcctgaaggcctcggacaccgccatgtattactgtgcacgctcagtcggccctatggactactggggccgcggcaccctggtcactgtctcctctgatcaggagcccaaatcttctgacaaaactcacacatctccaccgtgcccagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgttgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatga |
019008 | 86 | MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCRTSENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIKGGGGSGGGGSGGGGASEVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPMDYWGRGTLVTVSSDQEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
019009 | 87 | aagcttgccgccatggaagccccagctcagcttctcttcctcctgctactctggctcccagataccaccggtgaaattgtgttgacacagtctccagccaccctgtctttgtctccaggcgaaagagccaccctctcctgccgaacaagtgaaaatgtttacagctacttagcctggtaccaacagaaacctggccaggctcctaggctcctcatctattttgcaaaaaccttagcagaaggaattccagccaggttcagtggcagtggatccgggacagacttcactctcaccatcagcagcctagagcctgaagattttgcagtttattactgtcaacatcattccgataatccgtggacattcggccaagggaccaaggtggaaatcaaaggtggcggtggctcgggcggtggtggatctggaggaggtggggctagcgaggtgcagctggtgcagtctggagcagaggtgaaaaagcccggagagtctctgaggatttcctgtaagggatccggttactcattcactggctacaatatgaactgggtgcgccagatgcccgggaaaggcctggagtggatgggcaatattgatccttattatggtggtactacctacaaccggaagttcaagggccaggtcactatctccgccgacaagtccatcagcaccgcctacctgcaatggagcagcctgaaggcctcggacaccgccatgtattactgtgcacgctcagtcggccctatggactactggggccgcggcaccctggtcactgtctcctctgatcaggagcccaaatcttctgacaaaactcacacatctccaccgtgcccagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatga |
019009 | 88 | MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCRTSENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIKGGGGSGGGGSGGGGASEVQLVQSGAEVKKPGESLRISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPMDYWGRGTLVTVSSDQEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510137983.8A CN105012953B (zh) | 2005-07-25 | 2006-07-25 | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70249905P | 2005-07-25 | 2005-07-25 | |
US60/702,499 | 2005-07-25 | ||
US80059506P | 2006-05-16 | 2006-05-16 | |
US60/800,595 | 2006-05-16 | ||
PCT/US2006/029038 WO2007014278A2 (en) | 2005-07-25 | 2006-07-25 | B-cell reduction using cd37-specific and cd20-specific binding molecules |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510137983.8A Division CN105012953B (zh) | 2005-07-25 | 2006-07-25 | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101282745A CN101282745A (zh) | 2008-10-08 |
CN101282745B true CN101282745B (zh) | 2015-04-29 |
Family
ID=37683960
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510137983.8A Expired - Fee Related CN105012953B (zh) | 2005-07-25 | 2006-07-25 | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 |
CN200680027227.9A Expired - Fee Related CN101282745B (zh) | 2005-07-25 | 2006-07-25 | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510137983.8A Expired - Fee Related CN105012953B (zh) | 2005-07-25 | 2006-07-25 | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 |
Country Status (29)
Country | Link |
---|---|
US (7) | US10307481B2 (zh) |
EP (4) | EP2298815B1 (zh) |
JP (3) | JP5740076B2 (zh) |
KR (1) | KR101251157B1 (zh) |
CN (2) | CN105012953B (zh) |
AU (1) | AU2006272555B2 (zh) |
BR (1) | BRPI0614184A8 (zh) |
CA (1) | CA2616395C (zh) |
CO (1) | CO6160337A2 (zh) |
CR (1) | CR9761A (zh) |
DK (2) | DK1912675T3 (zh) |
EC (1) | ECSP088133A (zh) |
ES (2) | ES2539250T3 (zh) |
HK (3) | HK1155761A1 (zh) |
HR (2) | HRP20140338T1 (zh) |
HU (1) | HUE026303T2 (zh) |
IL (2) | IL188345A (zh) |
NI (1) | NI200800032A (zh) |
NO (1) | NO20080217L (zh) |
NZ (3) | NZ564764A (zh) |
PL (2) | PL2298815T3 (zh) |
PT (2) | PT2298815E (zh) |
RS (2) | RS53318B (zh) |
RU (1) | RU2423381C2 (zh) |
SG (2) | SG10201403526YA (zh) |
SI (2) | SI1912675T1 (zh) |
UA (1) | UA97469C2 (zh) |
WO (1) | WO2007014278A2 (zh) |
ZA (1) | ZA200800692B (zh) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US8563592B2 (en) | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
US6894071B2 (en) | 2001-11-01 | 2005-05-17 | Spectrum Pharmaceuticals, Inc. | Medical compositions for intravesical treatment of bladder cancer |
SI1912675T1 (sl) * | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
AU2007213476B2 (en) * | 2006-02-09 | 2013-03-28 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment involving determination of tumor enzyme level |
EP1996716B1 (en) | 2006-03-20 | 2011-05-11 | The Regents of the University of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
CA2654317A1 (en) * | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
JP2010507394A (ja) * | 2006-10-24 | 2010-03-11 | トルービオン ファーマスーティカルズ インコーポレイテッド | 改良免疫糖タンパク質のための物質および方法 |
US7846434B2 (en) | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
AU2008266952A1 (en) * | 2007-06-12 | 2008-12-24 | Trubion Pharmaceuticals, Inc. | Anti-CD20 therapeutic compositions and methods |
PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
WO2009032949A2 (en) * | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
EP2206775B1 (en) | 2007-09-26 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody |
CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
EP2209498A2 (en) * | 2007-10-03 | 2010-07-28 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
US20090169550A1 (en) * | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
PT2132228E (pt) * | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
LT2708559T (lt) | 2008-04-11 | 2018-06-11 | Chugai Seiyaku Kabushiki Kaisha | Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių |
US20090269339A1 (en) * | 2008-04-29 | 2009-10-29 | Genentech, Inc. | Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody |
EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
JP2012508774A (ja) * | 2008-11-13 | 2012-04-12 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Cd37免疫治療薬併用療法およびその使用 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
ES2712732T3 (es) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
HUE041426T2 (hu) | 2009-11-02 | 2019-05-28 | Univ Washington | Terápiás nukleáz-készítmények és eljárások |
CA2782333C (en) | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
US9260529B2 (en) * | 2010-02-24 | 2016-02-16 | The University Of Washington Through Its Center For Commercialization | Molecules that bind CD180, compositions and methods of use |
RU2610662C9 (ru) | 2010-03-12 | 2017-07-24 | Иммьюноджен, Инк. | Cd37-связывающие молекулы и их иммуноконъюгаты |
US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
JP6018622B2 (ja) * | 2011-04-01 | 2016-11-02 | イミュノジェン, インコーポレイテッド | Cd37結合性分子及びその免疫複合体 |
JP2014518615A (ja) * | 2011-04-22 | 2014-08-07 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 |
KR102161657B1 (ko) | 2011-04-29 | 2020-10-06 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 치료적 뉴클레아제 조성물 및 방법 |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
RU2658438C2 (ru) * | 2011-12-13 | 2018-06-21 | Нордик Нановектор Аса | Химерное терапевтическое антитело нн1 против cd-37 |
US20130287797A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
JP2015517512A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cd37抗体の更なる薬剤との併用 |
JP2015517511A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cd37抗体とice(イフォスファミド、カルボプラチン、エトポシド)の併用 |
US20160237152A1 (en) * | 2012-12-21 | 2016-08-18 | The Regents Of The University Of California | Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10738132B2 (en) | 2013-01-14 | 2020-08-11 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
US10228452B2 (en) | 2013-06-07 | 2019-03-12 | Hand Held Products, Inc. | Method of error correction for 3D imaging device |
BR112015030457A2 (pt) * | 2013-06-07 | 2017-08-22 | Nordic Nanovector As | Método para regular positivamente a expressão de antígeno |
JP6510518B2 (ja) | 2013-08-01 | 2019-05-08 | アジェンシス,インコーポレイテッド | Cd37タンパク質に結合する抗体薬物結合体(adc) |
CA2929119C (en) * | 2013-10-30 | 2023-03-14 | Trans Union Llc | Systems and methods for measuring effectiveness of marketing and advertising campaigns |
US10988745B2 (en) | 2013-10-31 | 2021-04-27 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
US10213513B2 (en) * | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
AU2015353416C1 (en) | 2014-11-26 | 2022-01-27 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CD38 |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
MA44391A (fr) * | 2015-06-08 | 2019-01-23 | Debiopharm Int Sa | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 |
SG10201913625XA (en) | 2015-08-07 | 2020-03-30 | Imaginab Inc | Antigen binding constructs to target molecules |
JP6890581B2 (ja) * | 2015-08-28 | 2021-06-18 | デビオファーム インターナショナル, エス. アー. | Cd37の検出のための抗体およびアッセイ |
EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3 BINDING POLYPEPTIDES |
JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Cd3及びpsmaに結合するヘテロ二量体抗体 |
JP2019503363A (ja) * | 2015-12-22 | 2019-02-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 急性リンパ芽球性白血病を治療するための二重特異性の抗cd20/抗cd3抗体 |
CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
EP3475304B1 (en) | 2016-06-28 | 2022-03-23 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
EP4410378A3 (en) | 2016-07-01 | 2024-10-09 | Resolve Therapeutics, LLC | Optimized binuclease fusions and methods |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
PE20191034A1 (es) | 2016-10-14 | 2019-08-05 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1 |
US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018119474A2 (en) * | 2016-12-23 | 2018-06-28 | Remd Biotherapeutics, Inc. | Immunotherapy using antibodies that bind programmed death 1 (pd-1) |
US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
NZ757603A (en) * | 2017-03-31 | 2024-05-31 | Genmab Holding B V | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたil−2 fc融合タンパク質 |
CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
ES2714952B2 (es) * | 2018-05-18 | 2020-07-10 | Productos Agrovin S A | Procedimiento y equipo para el remontado durante la maceracion de la vendimia |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
CA3099928A1 (en) * | 2018-06-22 | 2019-12-26 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 and cd19 |
WO2020004337A1 (ja) * | 2018-06-27 | 2020-01-02 | 国立大学法人名古屋大学 | Cd37特異的キメラ抗原レセプター |
SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
JP2022523946A (ja) | 2019-03-01 | 2022-04-27 | ゼンコア インコーポレイテッド | Enpp3およびcd3に結合するヘテロ二量体抗体 |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
CN113980130B (zh) * | 2020-07-27 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化cd37和双特异性cd19-人源化cd37 car-t细胞 |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
TW202330041A (zh) * | 2021-10-18 | 2023-08-01 | 日商第一三共股份有限公司 | 抗cd37抗體-藥物結合物 |
WO2023133488A1 (en) * | 2022-01-06 | 2023-07-13 | The General Hospital Corporation | Methods of cell ablation |
Family Cites Families (418)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4460559A (en) | 1980-03-03 | 1984-07-17 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4460561A (en) | 1980-03-03 | 1984-07-17 | Goldenberg M David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4818709A (en) | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
US4460459A (en) | 1983-02-16 | 1984-07-17 | Anschutz Mining Corporation | Sequential flotation of sulfide ores |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4624846A (en) | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4782840A (en) | 1984-03-02 | 1988-11-08 | Neoprobe Corporation | Method for locating, differentiating, and removing neoplasms |
US4935495A (en) | 1984-12-21 | 1990-06-19 | Oncogen | Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas |
US4906562A (en) | 1984-12-21 | 1990-03-06 | Oncogen | Monocolonal antibodies and antigen for human non-small cell lung carcinomas |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US5656266A (en) | 1985-11-19 | 1997-08-12 | Schering Corporation | Method of using interleukin-4 |
US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
US4932412A (en) | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
FI102355B1 (fi) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
WO1989008114A1 (en) | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5217713A (en) | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
CA2006408A1 (en) | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5098833A (en) | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5897861A (en) | 1989-06-29 | 1999-04-27 | Medarex, Inc. | Bispecific reagents for AIDS therapy |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US5980896A (en) | 1989-06-30 | 1999-11-09 | Bristol-Myers Squibb Company | Antibodies reactive with human carcinomas |
EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
DE69030579T2 (de) | 1989-09-20 | 1997-11-13 | Abbott Lab | Verfahren zur herstellung von fusionsproteinen |
US6018031A (en) | 1989-10-20 | 2000-01-25 | Trustees Of Dartmouth College | Binding agents specific for IgA receptor |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
AU645783B2 (en) | 1990-01-23 | 1994-01-27 | Tanox Biosystems, Inc. | Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor |
WO1991013166A1 (en) | 1990-03-02 | 1991-09-05 | Abbott Biotech, Inc. | Antibody constructs with enhanced binding affinity |
US20030219446A1 (en) | 1990-03-26 | 2003-11-27 | Bristol-Myers Squibb Company | Ligand for CD28 receptor on B cells and methods |
US5580756A (en) | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
GB9009106D0 (en) | 1990-04-23 | 1990-06-20 | 3I Res Expl Ltd | Processes and intermediates for synthetic antibody derivatives |
JPH06508501A (ja) | 1990-07-02 | 1994-09-29 | ブリストル―マイアーズ スクイブ カンパニー | B細胞上のcd28レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法 |
US5023264A (en) | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5023263A (en) | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5130307A (en) | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
US5233036A (en) | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
EP0585257A4 (en) | 1991-03-28 | 1995-02-22 | Univ Minnesota | DNA AND AMINO ACID SEQUENCE SPECIFIC TO NATURAL K KILLER CELLS. |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
ATE170559T1 (de) | 1991-05-31 | 1998-09-15 | Genentech Inc | Behandlung der hiv-assoziierten immun- thrombopenie purpura |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
DE122007000078I2 (de) | 1991-06-27 | 2011-01-13 | Bristol Myers Squibb Co | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
AU2143992A (en) | 1991-08-16 | 1993-03-16 | Vical, Inc. | Composition and method for treating cystic fibrosis |
US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
US6472510B1 (en) | 1992-02-14 | 2002-10-29 | Bristol-Myers Squibb Company | CD40 receptor ligands |
US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
DE69327620T2 (de) | 1992-08-18 | 2000-08-03 | Centro De Immunologia Molecular, Ciudad De La Habana | Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
ZA936260B (en) | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
WO1994009034A1 (en) | 1992-10-12 | 1994-04-28 | Agen Limited | Clot directed anticoagulant, process for making same and methods of use |
US5411967A (en) | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
US5480988A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5480989A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
US5262423A (en) | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
US6482919B2 (en) | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5597707A (en) | 1993-04-15 | 1997-01-28 | Bristol-Myers Squibb Company | Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use |
US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US5795572A (en) | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
ATE188487T1 (de) | 1993-09-02 | 2000-01-15 | Dartmouth College | Anti-gp39 antikoerper und deren verwendungen |
US5869049A (en) | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
GB9412166D0 (en) | 1993-09-22 | 1994-08-10 | Medical Res Council | Retargetting antibodies |
DE69414870T2 (de) | 1993-09-22 | 1999-05-12 | Medical Research Council, London | Antikoerper mit geaenderter zielrichtung |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5385910A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
US5385909A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
JP3745772B2 (ja) | 1993-12-17 | 2006-02-15 | ノバルティス アクチエンゲゼルシャフト | 免疫抑制剤として有用なラパマイシン誘導体 |
US5389639A (en) | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
US6380369B1 (en) | 1994-01-27 | 2002-04-30 | Human Genome Sciences, Inc. | Human DNA mismatch repair proteins |
CA2182498A1 (en) | 1994-02-01 | 1995-08-10 | William J. Larochelle | Fusion proteins that include antibody and nonantibody portions |
WO1995024220A1 (en) | 1994-03-07 | 1995-09-14 | Medarex, Inc. | Bispecific molecules having clinical utilities |
DE69529649T2 (de) | 1994-03-17 | 2003-12-18 | Merck Patent Gmbh | Anti-egfr einkettige fvs und anti-egfr antikoerper |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
NZ285395A (en) | 1994-05-02 | 1998-10-28 | Novartis Ag | Chimeric antibody, cancer treatment |
US5945273A (en) | 1997-06-03 | 1999-08-31 | Human Genome Sciences, Inc. | Human oxalyl-coa decarboxylase |
US5463048A (en) | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
DK0807183T3 (da) | 1994-08-26 | 2001-03-05 | Aventis Pharma Gmbh | Genterapi af sygdomme, der fremkaldes af immunsystemet, ved hjælp af et cellespecifikt aktivt stof, der reguleres af cellec |
US6380169B1 (en) | 1994-08-31 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Metal complex containing oligonucleoside cleavage compounds and therapies |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5491231A (en) | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US6383814B1 (en) | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
DK0833828T3 (da) | 1995-06-09 | 2003-03-17 | Novartis Ag | Rapamycinderivater |
GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
US5866330A (en) | 1995-09-12 | 1999-02-02 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
WO1997013529A1 (en) | 1995-10-13 | 1997-04-17 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxin containing a disulfide-stabilized antibody fragment |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6379966B2 (en) | 1999-02-26 | 2002-04-30 | Mirus Corporation | Intravascular delivery of non-viral nucleic acid |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
GB2310894A (en) | 1996-03-06 | 1997-09-10 | Clive William Efford | Multi-engine drive unit |
IL125928A (en) | 1996-03-20 | 2002-11-10 | Bristol Myers Squibb Co | The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations |
EP1186300A1 (en) | 1996-03-20 | 2002-03-13 | Bristol-Myers Squibb Company | Pharmaceutical compositions useful for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways |
DE19613691A1 (de) | 1996-04-05 | 1997-10-09 | Boehringer Ingelheim Int | Arzneimittel für die Behandlung von Tumorerkrankungen |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
BR9710357A (pt) | 1996-07-12 | 1999-08-17 | Genentech Inc | Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
EP0938506B1 (en) | 1996-07-16 | 2003-11-05 | Plückthun, Andreas, Prof. Dr. | Immunoglobulin superfamily domains and fragments with increased solubility |
US5846948A (en) | 1996-08-30 | 1998-12-08 | Arch Development Corporation | Herpes simplex virus ORF P is a repressor of viral protein synthesis |
GB9618477D0 (en) | 1996-09-04 | 1996-10-16 | Univ Leeds | Gene therapy |
US6368598B1 (en) | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
US5972361A (en) | 1996-10-25 | 1999-10-26 | The Procter & Gamble Company | Cleansing products |
US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
DE19651443A1 (de) | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
KR19980066046A (ko) | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
EP0860445A1 (en) | 1997-02-18 | 1998-08-26 | Hoechst Aktiengesellschaft | New nucleotide sequences for the cell cycle regulated expression of structural genes |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
RU2195946C2 (ru) | 1997-03-11 | 2003-01-10 | Ле Лабораториз Аетерна Инк. | Противоопухолевые терапевтические средства, включающие комбинацию экстракта хряща и антинеопластического агента, обеспечивающие высокую эффективность действия при низких токсических побочных эффектах |
EP0970101A2 (en) | 1997-03-20 | 2000-01-12 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
DK0999853T3 (da) | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
AU757627B2 (en) | 1997-06-24 | 2003-02-27 | Genentech Inc. | Methods and compositions for galactosylated glycoproteins |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
WO1999002567A2 (en) | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
US6383746B1 (en) | 1997-10-23 | 2002-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Functional promoter for CCR5 |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
US6383811B2 (en) | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
EP1469883A2 (en) | 1998-02-19 | 2004-10-27 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
HUP0100813A3 (en) | 1998-02-25 | 2003-08-28 | Lexigen Pharmaceuticals Corp L | Enhancing the circulating half-life of antibody-based fusion proteins |
US6383481B1 (en) | 1998-03-30 | 2002-05-07 | Japan Immunoresearch Laboratories Co., Ltd. | Method for transplantation of hemopoietic stem cells |
DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6284536B1 (en) | 1998-04-20 | 2001-09-04 | The Regents Of The University Of California | Modified immunoglobin molecules and methods for use thereof |
EE200000605A (et) | 1998-04-22 | 2002-04-15 | Genvec, Inc. | Adenoviiruse efektiivne puhastamine |
GB9809280D0 (en) | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
US7052872B1 (en) | 1999-06-22 | 2006-05-30 | Immunomedics, Inc. | Bi-specific antibodies for pre-targeting diagnosis and therapy |
AU750414B2 (en) | 1998-07-13 | 2002-07-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
JP2002521053A (ja) | 1998-07-28 | 2002-07-16 | マイクロメット アーゲー | ヘテロミニ体 |
ATE414536T1 (de) | 1998-08-11 | 2008-12-15 | Biogen Idec Inc | Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20- antikörpern |
US6383794B1 (en) | 1998-08-24 | 2002-05-07 | Uab Research Foundation | Methods of producing high titer recombinant adeno-associated virus |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
WO2000027885A1 (fr) | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau popypeptide chimerique |
EP1949910A1 (en) | 1998-11-09 | 2008-07-30 | Biogen Idec, Inc. | Treatment of chronic lymphocytic leukemia (CLL) using chimeric anti-CD20 antibody. |
JP2002529429A (ja) | 1998-11-09 | 2002-09-10 | アイデック・ファーマシューティカルズ・コーポレイション | Bmtまたはpbsc移植を受ける患者のキメラ化抗cd20抗体による治療。 |
US6380371B1 (en) | 1998-12-10 | 2002-04-30 | The Regents Of The University Of California | Endoglycan: a novel protein having selectin ligand and chemokine presentation activity |
KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
EP1151002A4 (en) | 1999-01-29 | 2002-05-02 | Imclone Systems Inc | KDR-SPECIFIC ANTIBODIES AND USES THEREOF |
US6383276B1 (en) | 1999-03-12 | 2002-05-07 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
US6383753B1 (en) | 1999-03-31 | 2002-05-07 | Regents Of The University Of Michigan | Yeast mammalian regulators of cell proliferation |
AU4476600A (en) | 1999-04-22 | 2000-11-10 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
GB9909925D0 (en) | 1999-04-29 | 1999-06-30 | Pharmacia & Upjohn Spa | Combined preparations comprising anthracycline derivatives |
US6358596B1 (en) * | 1999-04-27 | 2002-03-19 | The Standard Register Company | Multi-functional transparent secure marks |
MXPA01011279A (es) | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
CA2372400C (en) | 1999-05-19 | 2010-04-27 | Lexigen Pharmaceuticals Corp. | Expression and export of interferon-alpha proteins as fc fusion proteins |
EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
US6380382B1 (en) | 1999-06-30 | 2002-04-30 | Millennium Pharmaceuticals, Inc. | Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses |
DE19930748C2 (de) | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
CA2379274A1 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
ES2277846T3 (es) | 1999-07-29 | 2007-08-01 | Medarex, Inc. | Anticuerpos monoclonales humanos para antigeno prostatico especifico. |
DE60037896D1 (de) | 1999-07-29 | 2008-03-13 | Medarex Inc | Menschliche antikörper gegen her2/neu |
WO2001009186A2 (en) | 1999-07-30 | 2001-02-08 | Medarex, Inc. | Therapeutic compounds comprised of anti-fc receptor binding agents |
US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
JP2003513012A (ja) | 1999-08-11 | 2003-04-08 | アイデック ファーマスーティカルズ コーポレイション | 抗cd20抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 |
AU6929100A (en) | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
ES2219388T3 (es) | 1999-08-24 | 2004-12-01 | Ariad Gene Therapeutics, Inc. | 28-epi-rapalogos. |
WO2001034194A1 (en) | 1999-11-08 | 2001-05-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US20020028178A1 (en) | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
WO2001062144A1 (en) | 2000-02-25 | 2001-08-30 | Health Research, Inc. | Method for transdermal sampling of analytes |
AU2001247737A1 (en) | 2000-03-24 | 2001-10-08 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2 |
CN1981868A (zh) | 2000-03-31 | 2007-06-20 | 拜奥根Idec公司 | 抗细胞因子抗体或拮抗剂与抗-cd20在b细胞淋巴瘤治疗中的联合应用 |
EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
EP1939203B1 (en) | 2000-04-25 | 2014-11-19 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform |
WO2001080884A1 (en) | 2000-04-25 | 2001-11-01 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
AU5720601A (en) | 2000-04-26 | 2001-11-07 | Elusys Therapeutics Inc | Bispecific molecules and uses thereof |
KR100643818B1 (ko) | 2000-05-08 | 2006-11-10 | 셀덱스 쎄라퓨틱스, 인크. | 수상세포에 대한 인간 모노클로날 항체 |
US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
US20020103345A1 (en) | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
EP2052742A1 (en) | 2000-06-20 | 2009-04-29 | Biogen Idec Inc. | Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
WO2001097843A2 (en) | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
EP1297142B1 (en) | 2000-06-29 | 2009-01-14 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
JP2004502742A (ja) | 2000-07-12 | 2004-01-29 | アイデック ファーマスーティカルズ コーポレイション | B細胞を消滅させる抗体及び免疫調節抗体を併用するb細胞悪性疾患の治療関連出願 |
JP2004505251A (ja) | 2000-07-19 | 2004-02-19 | オルボテック リミテッド | 電気回路の電気的試験のための装置および方法 |
US20020025317A1 (en) | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
AU2001282862A1 (en) | 2000-07-24 | 2002-02-05 | Florida State University Research Foundation | Method and apparatus for removing minute particles from a surface |
EP1307490B1 (de) | 2000-08-11 | 2007-04-18 | Ruprecht-Karls-Universität Heidelberg | Fv-konstrukte mit beeinflussbarer affinitat zu einer zu bindenden substanz |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002034790A1 (en) | 2000-10-20 | 2002-05-02 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2433877C (en) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
NZ545176A (en) | 2001-01-29 | 2008-05-30 | Biogen Idec Inc | Modified antibodies reactive with CD20 and methods of use |
WO2002060485A2 (en) | 2001-01-31 | 2002-08-08 | Idec Pharmaceuticals Corporation | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
CA2437814C (en) | 2001-02-12 | 2008-05-13 | Medarex, Inc. | Human monoclonal antibodies to fc alpha receptor (cd89) |
EP1366067B1 (en) | 2001-03-07 | 2012-09-26 | Merck Patent GmbH | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2002072141A2 (en) | 2001-03-09 | 2002-09-19 | William Herman | Targeted ligands |
EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
US20020197256A1 (en) | 2001-04-02 | 2002-12-26 | Genentech, Inc. | Combination therapy |
US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
US20030008923A1 (en) | 2001-06-01 | 2003-01-09 | Wyeth | Antineoplastic combinations |
CN1966525A (zh) | 2001-06-13 | 2007-05-23 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
JP2005515161A (ja) | 2001-06-14 | 2005-05-26 | インターミューン インコーポレイテッド | γ−インターフェロンおよびB細胞特異的抗体の併用療法 |
US20020196854A1 (en) | 2001-06-15 | 2002-12-26 | Jongil Kim | Fast video encoder using adaptive hierarchical video processing in a down-sampled domain |
JP2005538706A (ja) * | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ, | スーパーヒト化抗体 |
US20030026780A1 (en) | 2001-07-18 | 2003-02-06 | Hood Leroy E. | Innate immunity mediated methods of treating pathological conditions |
AU2002339863A1 (en) | 2001-08-31 | 2003-03-18 | Abmaxis, Inc. | Multivalent protein conjugate with multiple ligand-binding domains of receptors |
ATE346866T1 (de) | 2001-09-14 | 2006-12-15 | Affimed Therapeutics Ag | Multimerische, einzelkettige, tandem-fv- antikörper |
US7355012B2 (en) * | 2001-09-26 | 2008-04-08 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells |
EP1487487A2 (en) | 2001-09-28 | 2004-12-22 | Elusys Therapeutics, Inc. | Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
EP1439857B1 (en) | 2001-10-12 | 2009-02-25 | Schering Corporation | USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES |
DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
DE60127143T2 (de) | 2001-11-14 | 2007-11-15 | Affimed Therapeutics Ag | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung |
PL372144A1 (en) | 2001-12-26 | 2005-07-11 | Immunomedics, Inc. | Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains |
CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
US8361464B2 (en) | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20030219436A1 (en) | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
CA2379586A1 (en) | 2002-04-10 | 2003-10-10 | William Herman | Fluid targeted ligands |
JP4518941B2 (ja) | 2002-04-26 | 2010-08-04 | 中外製薬株式会社 | アゴニスト抗体のスクリーニング方法 |
US7026330B2 (en) | 2002-05-30 | 2006-04-11 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
EP1572131B1 (en) | 2002-10-08 | 2016-07-06 | Immunomedics, Inc. | Antibody therapy |
JP5179702B2 (ja) | 2002-10-10 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 受容体Erb−B1に対する医薬組成物 |
PT2891666T (pt) | 2002-10-16 | 2017-09-22 | Purdue Pharma Lp | Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização |
MXPA05004022A (es) | 2002-10-17 | 2005-10-05 | Genmab As | Anticuerpos monoclonales humanos contra cd20. |
PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
EP1583503A4 (en) | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF |
ES2388280T3 (es) | 2002-12-20 | 2012-10-11 | Abbott Biotherapeutics Corp. | Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos |
ATE488600T1 (de) | 2002-12-23 | 2010-12-15 | Bristol Myers Squibb Co | Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion |
CA2414148A1 (en) | 2002-12-30 | 2004-06-30 | William Herman | Targeted ligands |
US20050008625A1 (en) * | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
JP3803790B2 (ja) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
WO2004076489A1 (en) | 2003-02-25 | 2004-09-10 | Medinnova As | Modified antibody |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
WO2005021710A2 (en) | 2003-06-02 | 2005-03-10 | University Of Miami | Chimeric molecules and methods of use |
CN1279056C (zh) | 2003-06-06 | 2006-10-11 | 马菁 | 肿瘤相关抗原sm5-1的特异性抗体及其应用 |
WO2005000898A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
AU2004255216B2 (en) | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US6864837B2 (en) | 2003-07-18 | 2005-03-08 | Ems Technologies, Inc. | Vertical electrical downtilt antenna |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
CA2536288A1 (en) | 2003-08-21 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Cancer metastasis inhibitor |
CA2542239C (en) | 2003-10-16 | 2014-12-30 | Micromet Ag | Multispecific deimmunized cd3-binders |
WO2005047334A1 (en) | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical. Co., Ltd. | Igg fc fragment for a drug carrier and method for the preparation thereof |
AU2004309347B2 (en) | 2003-12-19 | 2010-03-04 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
WO2005064343A1 (en) | 2003-12-22 | 2005-07-14 | Novartis Ag | Biomarkers for sensitivity of proliferative diseases to mtor inhibitors |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
DK1709081T3 (da) | 2004-01-16 | 2011-06-06 | Regeneron Pharma | Fusionspolypeptider, der kan aktivere receptorer |
CA2555503C (en) | 2004-02-16 | 2018-03-27 | Micromet Ag | Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto |
AR047988A1 (es) | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
EP1730194B1 (en) | 2004-03-30 | 2011-11-02 | Yissum Research Development Company of the Hebrew University of Jerusalem | Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
AU2005258336A1 (en) | 2004-06-03 | 2006-01-05 | Medarex, Inc. | Human monoclonal antibodies to Fc gamma receptor I (CD64) |
EP1765400A2 (en) | 2004-06-04 | 2007-03-28 | Genentech, Inc. | Method for treating lupus |
KR20150092374A (ko) | 2004-06-04 | 2015-08-12 | 제넨테크, 인크. | 다발성 경화증의 치료 방법 |
US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
JP2008512987A (ja) | 2004-07-22 | 2008-05-01 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 結合分子 |
WO2007011363A2 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
MX2007002856A (es) | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
ZA200702335B (en) | 2004-10-05 | 2009-05-27 | Genentech Inc | Method for treating vasculitis |
ATE525400T1 (de) | 2004-12-01 | 2011-10-15 | Trion Pharma Gmbh | Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie |
CA2587143C (en) | 2004-12-08 | 2017-12-05 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
KR100616666B1 (ko) | 2005-01-27 | 2006-08-28 | 삼성전기주식회사 | 카본나노튜브에 구아니딘기를 형성하는 방법,구아니딘기가 형성된 카본나노튜브를 기판에 부착하는방법 및 이에 따라 제조된 카본나노튜브 및 기판 |
DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
US8034902B2 (en) | 2005-05-04 | 2011-10-11 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against CD55 and CD59 and uses thereof |
US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
US20070014720A1 (en) | 2005-06-02 | 2007-01-18 | Gadi Gazit-Bornstein | Antibodies directed to CD20 and uses thereof |
SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
CN101267836A (zh) | 2005-07-25 | 2008-09-17 | 特鲁比昂药品公司 | 单剂量cd20特异性结合分子的用途 |
US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP4641476B2 (ja) | 2005-09-15 | 2011-03-02 | キヤノン株式会社 | プローブアレイの製造装置 |
MX2008008220A (es) | 2005-12-20 | 2009-03-04 | Morphosys Ag | Nueva coleccion de regiones hcdr3 y usos de las mismas. |
MX2008010561A (es) | 2006-02-15 | 2009-03-02 | Imclone Systems Inc | Anticuerpos funcionales. |
CA2654317A1 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
US7846434B2 (en) | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
JP2010507394A (ja) | 2006-10-24 | 2010-03-11 | トルービオン ファーマスーティカルズ インコーポレイテッド | 改良免疫糖タンパク質のための物質および方法 |
TW200902725A (en) | 2007-04-02 | 2009-01-16 | Genentech Inc | Biological markers predictive of rheumatoid arthritis response to B-cell antagonists |
WO2008153636A1 (en) | 2007-05-04 | 2008-12-18 | Cellsignaling Technology, Inc. | Phospho-specific antibodies to p13k regulatory subunit and uses thereof |
JP2010526120A (ja) | 2007-05-09 | 2010-07-29 | ノバルティス アーゲー | Pi3k脂質キナーゼ阻害剤としての置換イミダゾピリダジン |
CN101802197A (zh) | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC(ScFc)区、包含其的结合多肽及与其相关的方法 |
WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
WO2008152394A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
US7893060B2 (en) | 2007-06-12 | 2011-02-22 | F. Hoffmann-La Roche Ag | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
AU2008287195A1 (en) | 2007-07-06 | 2009-02-19 | Emergent Product Development Seattle, Llc | Binding peptides having a C-terminally disposed specific binding domain |
PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
ES2537352T3 (es) | 2007-09-12 | 2015-06-05 | Genentech, Inc. | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso |
EP2217590A4 (en) | 2007-09-17 | 2011-12-14 | Glaxosmithkline Llc | Pyridopyrimidine derivatives as PI3-kinase inhibitors |
EP2207781B1 (en) | 2007-09-24 | 2012-11-28 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
CN101878219B (zh) | 2007-09-27 | 2014-04-02 | 西班牙国家癌症研究中心 | 用于作为蛋白激酶抑制剂使用的咪唑并噻二唑类 |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
BRPI0817503B8 (pt) | 2007-10-05 | 2021-05-25 | Sstarbio Pte Ltd | derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa |
US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
BRPI0817681A2 (pt) | 2007-10-16 | 2015-04-14 | Wyeth Llc | Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase |
EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
JP5638955B2 (ja) | 2007-10-26 | 2014-12-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pi3キナーゼ阻害剤として有用なプリン誘導体 |
GB0721095D0 (en) | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
US7951832B2 (en) | 2007-10-31 | 2011-05-31 | Burnham Institute For Medical Research | Pyrazole derivatives as kinase inhibitors |
US20090131512A1 (en) | 2007-10-31 | 2009-05-21 | Dynavax Technologies Corp. | Inhibition of type I in IFN production |
GEP20125635B (en) | 2007-11-13 | 2012-09-10 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
US20090149458A1 (en) | 2007-11-27 | 2009-06-11 | Wyeth | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS |
KR20100086492A (ko) | 2007-11-27 | 2010-07-30 | 셀좀 리미티드 | Pi3k 억제제로서의 아미노 트리아졸 |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
JP2012508774A (ja) | 2008-11-13 | 2012-04-12 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Cd37免疫治療薬併用療法およびその使用 |
-
2006
- 2006-07-25 SI SI200631765T patent/SI1912675T1/sl unknown
- 2006-07-25 NI NI200800032A patent/NI200800032A/es unknown
- 2006-07-25 PL PL10181126T patent/PL2298815T3/pl unknown
- 2006-07-25 PL PL06788565T patent/PL1912675T3/pl unknown
- 2006-07-25 AU AU2006272555A patent/AU2006272555B2/en not_active Ceased
- 2006-07-25 CN CN201510137983.8A patent/CN105012953B/zh not_active Expired - Fee Related
- 2006-07-25 ES ES10181126.3T patent/ES2539250T3/es active Active
- 2006-07-25 KR KR1020087003703A patent/KR101251157B1/ko active IP Right Grant
- 2006-07-25 PT PT101811263T patent/PT2298815E/pt unknown
- 2006-07-25 HU HUE10181126A patent/HUE026303T2/hu unknown
- 2006-07-25 EP EP10181126.3A patent/EP2298815B1/en active Active
- 2006-07-25 CN CN200680027227.9A patent/CN101282745B/zh not_active Expired - Fee Related
- 2006-07-25 BR BRPI0614184A patent/BRPI0614184A8/pt not_active Application Discontinuation
- 2006-07-25 NZ NZ564764A patent/NZ564764A/en not_active IP Right Cessation
- 2006-07-25 DK DK06788565.7T patent/DK1912675T3/en active
- 2006-07-25 RS RS20140232A patent/RS53318B/en unknown
- 2006-07-25 RS RS20150399A patent/RS54088B1/en unknown
- 2006-07-25 US US11/493,132 patent/US10307481B2/en active Active
- 2006-07-25 SG SG10201403526YA patent/SG10201403526YA/en unknown
- 2006-07-25 SG SG200906066-6A patent/SG155912A1/en unknown
- 2006-07-25 EP EP06788565.7A patent/EP1912675B1/en active Active
- 2006-07-25 RU RU2008106893/10A patent/RU2423381C2/ru not_active IP Right Cessation
- 2006-07-25 ES ES06788565.7T patent/ES2460517T3/es active Active
- 2006-07-25 DK DK10181126.3T patent/DK2298815T3/en active
- 2006-07-25 NZ NZ606294A patent/NZ606294A/en not_active IP Right Cessation
- 2006-07-25 SI SI200631932T patent/SI2298815T1/sl unknown
- 2006-07-25 NZ NZ594275A patent/NZ594275A/xx not_active IP Right Cessation
- 2006-07-25 CA CA2616395A patent/CA2616395C/en not_active Expired - Fee Related
- 2006-07-25 PT PT67885657T patent/PT1912675E/pt unknown
- 2006-07-25 EP EP20120185719 patent/EP2586798A3/en not_active Withdrawn
- 2006-07-25 JP JP2008524109A patent/JP5740076B2/ja not_active Expired - Fee Related
- 2006-07-25 WO PCT/US2006/029038 patent/WO2007014278A2/en active Application Filing
- 2006-07-25 UA UAA200802255A patent/UA97469C2/uk unknown
- 2006-07-25 EP EP20100182256 patent/EP2295080A3/en not_active Withdrawn
-
2007
- 2007-12-23 IL IL188345A patent/IL188345A/en not_active IP Right Cessation
-
2008
- 2008-01-14 NO NO20080217A patent/NO20080217L/no not_active Application Discontinuation
- 2008-01-16 CO CO08003675A patent/CO6160337A2/es unknown
- 2008-01-23 ZA ZA2008/00692A patent/ZA200800692B/en unknown
- 2008-01-24 EC EC2008008133A patent/ECSP088133A/es unknown
- 2008-02-25 CR CR9761A patent/CR9761A/es unknown
- 2008-10-20 HK HK11110031.7A patent/HK1155761A1/zh not_active IP Right Cessation
- 2008-10-20 HK HK08111578.9A patent/HK1115820A1/zh not_active IP Right Cessation
-
2009
- 2009-03-25 HK HK09102857.9A patent/HK1125288A1/zh not_active IP Right Cessation
- 2009-05-07 US US12/437,507 patent/US20090214539A1/en not_active Abandoned
-
2012
- 2012-05-30 JP JP2012122847A patent/JP2012165760A/ja active Pending
-
2013
- 2013-03-15 US US13/836,377 patent/US20130266561A1/en not_active Abandoned
- 2013-03-15 US US13/836,163 patent/US20140010813A1/en not_active Abandoned
- 2013-03-15 US US13/836,103 patent/US10143748B2/en not_active Expired - Fee Related
- 2013-03-15 US US13/836,147 patent/US20140072562A1/en not_active Abandoned
-
2014
- 2014-04-08 HR HRP20140338TT patent/HRP20140338T1/hr unknown
- 2014-07-14 JP JP2014143931A patent/JP2014196350A/ja active Pending
-
2015
- 2015-03-22 IL IL237881A patent/IL237881A0/en unknown
- 2015-06-02 HR HRP20150591TT patent/HRP20150591T1/hr unknown
-
2018
- 2018-10-26 US US16/172,096 patent/US20190290755A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
《Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin"s lymphoma》;L. D. Piro等;《Annals of Oncology》;19991231;第10卷(第6期);655-661 * |
《Induction of Apoptosis in B Lymphoma Cell Lines by CytoxB37G,,a Small Modular ImmunoPharmaceutical (SMIP) That Binds CD37》;Martha Hayden-Ledbetter等;《BLOOD》;20031116;第102卷(第11期);摘要 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101282745B (zh) | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 | |
US20080279850A1 (en) | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules | |
US20080213273A1 (en) | Single dose use of CD20-specific binding molecules | |
US20100330089A1 (en) | Anti-cd20 therapeutic compositions and methods | |
WO2015116729A2 (en) | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders | |
JP2022105121A (ja) | Psma、nkg2dおよびcd16に結合するタンパク質 | |
AU2012203322B2 (en) | B-Cell Reduction Using CD37-Specific And CD20-Specific Binding Molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1125288 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC Free format text: FORMER OWNER: GENECRAFT INC. Effective date: 20110714 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20110714 Address after: Washington State Applicant after: Emergent Product Development Seattle LLC Address before: Washington State Applicant before: Terubion Pharmacy Co. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1125288 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Washington State Patentee after: ARP Trevor development limited liability company Address before: Washington State Patentee before: Emergent Product Development Seattle LLC |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150429 Termination date: 20200725 |
|
CF01 | Termination of patent right due to non-payment of annual fee |